Corium gets US patent for MicroCor transdermal system

Corium, a US-based biopharmaceutical firm, is focused on the development, manufacture and commercialization of specialty transdermal products.

The MicroCor system is a clinical-stage platform technology using dissolving microstructures for the safe, effective and convenient transdermal delivery of small molecules and biologics, including vaccines, peptides and proteins.

The company noted that the patent includes coverage of an array of microstructures, where the tips of the microstructures dissolve or biodegrade upon application to the skin, delivering a range of therapeutic agents including biologics, vaccines and small molecules.

Corium R&D vice-president and chief technology officer and a co-inventor on the patent Parminder Singh said: "Our microstructure design, with the therapeutic agent localized in the dissolvable tip, enables the transdermal delivery of a wide range of drug classes, especially where rapid onset of therapeutic effect is desired.

"MicroCor’s dissolving drug-in-tip platform offers patients a needle-free alternative to injections with short wear time, a flexible range of drug release profiles and enhanced safety due to the absence of sharps left behind after use."

According to the company, life of the new patent extends at least until September 2031 and MicroCor technology is also covered by its patents and patent filings relating to the applicator, the microstructure design, microstructure formulation compositions, manufacturing methods and packaging methodologies.